Welcome to our dedicated page for Nexgel Wt Exp 120126 SEC filings (Ticker: NXGLW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NexGel, Inc. filings document an operating company built around high-water-content hydrogel products for healthcare, consumer, diagnostic, drug-delivery and cosmetic applications. Its SEC records include current reports on material definitive agreements, asset purchase and exclusive license arrangements, contract-manufacturing-related agreements, and amendments affecting consideration and assumed obligations.
The company’s filings also cover capital-structure matters such as convertible promissory notes and private-placement financing, governance disclosures including executive appointments and employment arrangements, and Nasdaq continued-listing compliance notices. These records provide formal disclosure on NexGel’s operating agreements, securities terms, board and management changes, and public-company reporting obligations.
NexGel director Jerome B. Zeldis received a stock option grant on June 25, 2025 for 30,000 shares of common stock at an exercise price of $2.32 per share. The options were granted under the company's 2019 Long-Term Incentive Plan for board service through the 2026 Annual Meeting.
Key terms of the stock option grant:
- Vesting schedule: Equal monthly installments of 2,500 shares over 12 months starting July 31, 2025
- Expiration date: June 25, 2035
- Exercise price: $2.32 per share
- Accelerated vesting provision in case of Change in Control
This Form 4 filing indicates continued alignment of director compensation with shareholder interests through equity-based incentives. The 10-year exercise period and monthly vesting schedule are typical for director equity compensation plans.